Tumor-Penetrating iRGD Peptide Inhibits Metastasis

Kazuki N. Sugahara(Sanford Burnham Prebys Medical Discovery Institute), Gary B. Braun(University of California, Santa Barbara), Tatiana Hurtado de Mendoza(Sanford Burnham Prebys Medical Discovery Institute), Venkata Ramana Kotamraju(Sanford Burnham Prebys Medical Discovery Institute), Randall P. French(University of California San Diego), Andrew M. Lowy(University of California San Diego), Tambet Teesalu(Sanford Burnham Prebys Medical Discovery Institute), Erkki Ruoslahti(University of California, Santa Barbara)
Molecular Cancer Therapeutics
November 13, 2014
Cited by 135Open Access
Full Text

Abstract

Tumor-specific tissue-penetrating peptides deliver drugs into extravascular tumor tissue by increasing tumor vascular permeability through interaction with neuropilin (NRP). Here, we report that a prototypic tumor-penetrating peptide iRGD (amino acid sequence: CRGDKGPDC) potently inhibits spontaneous metastasis in mice. The antimetastatic effect was mediated by the NRP-binding RXXK peptide motif (CendR motif), and not by the integrin-binding RGD motif. iRGD inhibited migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. The peptide induced dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects were prominently displayed when the cells were seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins. The antimetastatic activity of iRGD may provide a significant additional benefit when this peptide is used for drug delivery to tumors.


Related Papers

No related papers found

Powered by citation graph analysis